- ICH GCP
- Rejestr badań klinicznych w USA
- Badanie kliniczne NCT06724276
Combined Treatment for Non-Healing Wounds in Chronic Lower Extremity Arterial Disease: A Comparative Study
Effectiveness of Combined Treatment Methods for Non-Healing Wounds in Patients With Chronic Lower Extremity Arterial Disease: A Comparative Study
Endovascular interventions, such as balloon angioplasty and stenting, are commonly used for PAD due to their proven safety and effectiveness. However, traditional treatments for chronic non-healing wounds are often insufficient. Advances in cell biotechnology, particularly fibroblast therapy, show promise for enhancing wound healing, as fibroblasts play a crucial role in tissue repair and inflammation.
This study aims to develop, assess, and evaluate the safety of a combined treatment approach that incorporates fibroblast therapy with existing methods for managing chronic non-healing wounds in PAD patients.
Przegląd badań
Status
Szczegółowy opis
Chronic obliterative diseases of the lower extremity arteries, or peripheral artery disease (PAD), result from systemic atherosclerosis and affect about 202 million adults globally. This condition, marked by progressive arterial stenosis or occlusion, is associated with significant risk factors such as diabetes, smoking, and hypertension. PAD can lead to symptoms ranging from pain and fatigue to severe complications like non-healing chronic wounds. These wounds impose a substantial economic burden on healthcare systems and significantly impact patients' quality of life.
In some countries, over 2.5 million people suffer from chronic non-healing ulcers, with high rates of recurrence and poor healing outcomes. Managing these wounds is costly, with significant indirect costs due to loss of productivity. Post-amputation survival rates are low, and traditional treatments often fail to fully address the issue.
Endovascular interventions, such as balloon angioplasty and stenting, are preferred for PAD due to their safety and effectiveness. However, current methods for treating chronic non-healing wounds remain insufficient. Recent advancements in cell biotechnology, particularly fibroblast therapy, show promise for improving wound healing. Fibroblasts play a key role in tissue repair and inflammation.
There is a need for more research on the effectiveness of combining fibroblast therapy with existing treatments for chronic non-healing wounds in PAD patients. Addressing this gap could lead to better treatment outcomes and improved quality of life for affected individuals.
The aim of this study is to develop, assess the effectiveness, and evaluate the safety of a combined treatment method for managing chronic non-healing wounds in patients with chronic obliterative disease of the lower extremity arteries.
Typ studiów
Zapisy (Rzeczywisty)
Faza
- Nie dotyczy
Kontakty i lokalizacje
Lokalizacje studiów
-
-
-
Astana, Kazachstan, 010000
- National Research Oncology Center
-
-
Kryteria uczestnictwa
Kryteria kwalifikacji
Wiek uprawniający do nauki
Akceptuje zdrowych ochotników
Płeć kwalifikująca się do nauki
Opis
Inclusion Criteria:
- Male and female patients aged 18 to 75 years inclusive.
- Patients with a history of confirmed stable intermittent lameness, the symptoms of which have been observed continuously for at least 3 months at the time of randomization.
- Patients with a diagnosis of PAD (code I 70.2 - I 70.9 according to the International Classification of Diseases, 10th revision [ICD - 10]), confirmed by the results of ultrasound duplex scanning of blood vessels.
- Patients whose smoking status remained stable for at least 3 months prior to randomization (for smokers).
- Patients with an ankle - brachial Doppler index value at rest ≤0.9.
- Patients with a long-term non-healing wound (more than 1 month) and intermittent claudication with a pain-free walking distance of less than 200 meters.
- Patients who, in the opinion of the investigator, are able to understand and comply with the study requirements.
- Before starting any examination procedures by the patient or, if applicable, its legal representative, a signed and dated written informed consent form, as well as any necessary processing permissions personal data.
Exclusion Criteria:
- Acute myocardial infarction (ACS), acute cerebrovascular accident (stroke)
- Pulmonary embolism (PE)
- Acute infectious diseases
- Patients who underwent reconstructive intervention on the arteries of the lower extremities (surgical or intravascular) in the last 3 months before randomization.
- Patients who underwent major cardiac surgery within 6 months prior to randomization.
- Patients with congestive heart failure III-IV functional class according to classification of the New York Heart Association.
- Patients with any other disease that significantly limits physical activity, or any other medical condition that, in the opinion of the investigator, may limit the patient's participation in the study.
- Patients with mental status disorders
- Patients with a history of hypersensitivity or allergy to a radiopaque substance, similar drugs or excipients.
- Patients who are pregnant or breastfeeding, or who plan to become pregnant before participating in this study or during the study, or who intend to become an egg donor within the same period of time.
- Progression of the underlying and concomitant disease
- High levels of creatinine and urea in a biochemical blood test (creatinine in women: more than 80.0 µmol / l; men: more than 110.0 µmol / l; ); ( Urea in adults under 60 years of age is more than 8.32 mmol/l, adults over 60 years of age are more than 7.5 mmol/l )
- Presence of peptic ulcer of the stomach and duodenum (DUD)
- Patients with total thrombosis of the vessels of the lower extremities
Plan studiów
Jak projektuje się badanie?
Szczegóły projektu
- Główny cel: Leczenie
- Przydział: Randomizowane
- Model interwencyjny: Przydział równoległy
- Maskowanie: Brak (otwarta etykieta)
Broń i interwencje
Grupa uczestników / Arm |
Interwencja / Leczenie |
|---|---|
|
Eksperymentalny: combined treatment
Combined treatment (balloon angioplasty or stenting + fibroblast transplantation). |
A balloon or a stent of the required size (according to the intrinsic diameter of the affected vessel) is delivered to the affected area, sequential balloon dilatation with exposure of up to 5 minutes or stenting of the vessel is performed. After completion, control angiography is performed with evaluation of the result. Instruments, introdjuncer are removed. Manual compression haemostasis (up to 20 minutes over the puncture site) followed by aseptic pressure dressing on the puncture site for 12 hours with bed rest. After surgery, fibroblasts will be applied to the wound for 24 hours. |
|
Aktywny komparator: Endovascular treatment
Endovascular interventions + traditional debridement. |
A balloon or a stent of the required size (according to the intrinsic diameter of the affected vessel) is delivered to the affected area, sequential balloon dilatation with exposure of up to 5 minutes or stenting of the vessel is performed. After completion, control angiography is performed with evaluation of the result. Instruments, introdjuncer are removed. Manual compression haemostasis (up to 20 minutes over the puncture site) followed by aseptic pressure dressing on the puncture site for 12 hours with bed rest. |
Co mierzy badanie?
Podstawowe miary wyniku
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
brachial-shoulder index
Ramy czasowe: 1 day, after 1 month, after 3 month, after 6 month
|
The Brachial-Shoulder Index (BSI, ratio) is a diagnostic measure used to assess blood flow and detect potential vascular abnormalities. It is calculated by dividing the systolic blood pressure (mmHg) at the shoulder by the systolic blood pressure (mmHg) at the arm (brachial artery). This index helps evaluate the presence of arterial blockages or compression between the shoulder and the arm, which can indicate peripheral vascular disease or other circulatory issues. A reduced BSI may suggest impaired blood flow (mm/sec) and is useful in diagnosing conditions related to upper limb circulation. |
1 day, after 1 month, after 3 month, after 6 month
|
Miary wyników drugorzędnych
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
dynamics of wound healing
Ramy czasowe: 1 day, after 1 month, after 3 month, after 6 month
|
The dynamics of wound healing refer to the process and progression of tissue repair following an injury. This process involves several key phases:Hemostasis, Inflammation, Proliferation, Maturation. The rate and quality of healing can be influenced by factors such as wound type, underlying health conditions, and treatment methods. Monitoring these dynamics ( in cm^2) helps assess the effectiveness of interventions and guide clinical decisions |
1 day, after 1 month, after 3 month, after 6 month
|
Inne miary wyników
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Number of participants
Ramy czasowe: in a month, 3 months, 6 months
|
The number of participants in the study will be analyzed. |
in a month, 3 months, 6 months
|
|
Analysis of participants' body weight
Ramy czasowe: in a month, 3 months, 6 months
|
Participants' body weight will be analyzed |
in a month, 3 months, 6 months
|
|
Assessment of the degree of oxygen saturation of the lower extremities
Ramy czasowe: in a month, 3 months, 6 months
|
During the study, the oxygen saturation level of the lower extremities will be assessed using a peripheral pulse oximeter. Since ischemia of the extremities affects the oxygen saturation level of the surrounding tissues. |
in a month, 3 months, 6 months
|
|
Results of the SF-12 questionnaire
Ramy czasowe: before the tretment, 3 months, 6 months
|
Before treatment, then 3 and 6 months after treatment, participants will complete the SF-12 questionnaire, which will take into account the physical condition, mental state and general condition of the participants. |
before the tretment, 3 months, 6 months
|
|
Activity of Daily Living Index - Bartell Index.
Ramy czasowe: before the tretment, 3 months after the treatment, 6 months after the treatment
|
The Barthel scale is an ordinal scale used to measure performance in daily living. Each performance element is rated on this scale with a set number of points assigned to each level or ranking. It uses ten variables that describe ADLs and mobility. A higher number is associated with a greater likelihood that you will be able to live at home with a degree of independence after discharge from the hospital. |
before the tretment, 3 months after the treatment, 6 months after the treatment
|
Współpracownicy i badacze
Sponsor
Daty zapisu na studia
Główne daty studiów
Rozpoczęcie studiów (Rzeczywisty)
Zakończenie podstawowe (Rzeczywisty)
Ukończenie studiów (Rzeczywisty)
Daty rejestracji na studia
Pierwszy przesłany
Pierwszy przesłany, który spełnia kryteria kontroli jakości
Pierwszy wysłany (Rzeczywisty)
Aktualizacje rekordów badań
Ostatnia wysłana aktualizacja (Rzeczywisty)
Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości
Ostatnia weryfikacja
Więcej informacji
Terminy związane z tym badaniem
Słowa kluczowe
Dodatkowe istotne warunki MeSH
- Choroby układu hormonalnego
- Choroby naczyniowe
- Choroby układu krążenia
- Choroby metaboliczne
- Zaburzenia metabolizmu glukozy
- Angiopatie cukrzycowe
- Powikłania cukrzycy
- Choroby skórne
- Owrzodzenie skóry
- Owrzodzenie nogi
- Neuropatie cukrzycowe
- Arterioskleroza
- Choroby okluzyjne tętnic
- Choroby naczyń obwodowych
- Owrzodzenie stopy
- Choroby żywieniowe i metaboliczne
- Choroby skóry i tkanki łącznej
- Cukrzyca
- Stopa cukrzycowa
- Choroba tętnic obwodowych
- Miażdżyca tętnic
- Arterioskleroza zarostowa
- Techniki śledcze
- Lecznictwo
- Procedury chirurgiczne, operacyjny
- Angioplastyka
- Cewnikowanie
- Procedury wewnątrznaczyniowe
- Naczyniowe procedury chirurgiczne
- Procedury chirurgiczne sercowo -naczyniowe
- Minimalnie inwazyjne procedury chirurgiczne
- Angioplastyka, balon
Inne numery identyfikacyjne badania
- NROC
Plan dla danych uczestnika indywidualnego (IPD)
Planujesz udostępniać dane poszczególnych uczestników (IPD)?
Informacje o lekach i urządzeniach, dokumenty badawcze
Bada produkt leczniczy regulowany przez amerykańską FDA
Bada produkt urządzenia regulowany przez amerykańską FDA
Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .